Floatz logo

Carboplatin

Mucinous Adenocarcinoma

National Cancer Institute (NCI)Small moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Mucinous Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Irinotecan
Stony Brook University
Phase 3BB
Docetaxel
National Cancer Institute (NCI)
Phase 3B
Eloxatin
University Hospital, Akershus
Phase 2CCC
Nivolumab
University Hospital, Akershus
Phase 2CCC
Ipilimumab
National Cancer Institute (NCI)
Phase 2CCC
Samuraciclib
University Health Network, Toronto
Phase 1/2CCC

Same molecule, other indications

Carboplatin is also rated in:

lung large cell carcinomaDormant
A
Indicative ·
80 / 100
View asset →
non-small cell squamous lung carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →